Skip to Content

MediciNova Inc MNOV

Morningstar Rating
$1.31 +0.01 (0.77%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MNOV is trading at a 60% premium.
Price
$1.32
Fair Value
$5.75
Uncertainty
Extreme
1-Star Price
$11.71
5-Star Price
$7.32
Economic Moat
Wwgt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MNOV is a good fit for your portfolio.

Trading Information

Previous Close Price
$1.30
Day Range
$1.291.35
52-Week Range
$1.262.56
Bid/Ask
$1.28 / $1.32
Market Cap
$64.25 Mil
Volume/Avg
8,005 / 22,276

Key Statistics

Price/Earnings (Normalized)
Price/Sales
64.25
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
13

Comparables

Valuation

Metric
MNOV
EWTX
DYN
Price/Earnings (Normalized)
Price/Book Value
1.073.318.11
Price/Sales
64.25
Price/Cash Flow
Price/Earnings
MNOV
EWTX
DYN

Financial Strength

Metric
MNOV
EWTX
DYN
Quick Ratio
18.7836.4920.28
Current Ratio
19.0737.0821.83
Interest Coverage
Quick Ratio
MNOV
EWTX
DYN

Profitability

Metric
MNOV
EWTX
DYN
Return on Assets (Normalized)
−11.45%−23.18%−77.53%
Return on Equity (Normalized)
−12.07%−24.45%−94.92%
Return on Invested Capital (Normalized)
−14.09%−28.92%−88.19%
Return on Assets
MNOV
EWTX
DYN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FgspztfzzSwrfd$565.6 Bil
Vertex Pharmaceuticals Inc
VRTX
NqpnhmlcSyhyfn$127.8 Bil
Regeneron Pharmaceuticals Inc
REGN
FtrnzgdlTjnjnrf$118.7 Bil
Moderna Inc
MRNA
MdbqpqvgDcr$46.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
KsjqnpkmzLvpjmw$29.7 Bil
argenx SE ADR
ARGX
FxxqqxgWtcx$29.3 Bil
BioNTech SE ADR
BNTX
BfjvstwjChsn$20.7 Bil
Biomarin Pharmaceutical Inc
BMRN
RcxfxtspmVbvvk$16.1 Bil
United Therapeutics Corp
UTHR
GdvxyspmdZwvb$15.0 Bil
Incyte Corp
INCY
LcsthhghyVycxmr$13.5 Bil

Sponsor Center